Key Points
- CEO Daniel Patrick O’Day sold 15,000 Gilead shares on June 1 at an average price of $131.46, totaling about $1.97 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan and reduced his ownership by 2.37%.
- Gilead recently beat earnings expectations, reporting $2.03 EPS versus the $1.91 consensus and revenue of $6.96 billion, up 4.4% year over year. The company also maintained strong profitability, with a net margin of 30.99% and return on equity of 48.19%.
- Analysts remain broadly positive on GILD, with 26 Buy ratings and 3 Hold ratings, and a consensus price target of $156.93. The stock also offers a quarterly dividend of $0.82, or $3.28 annually, for a 2.6% yield.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares of the company's stock, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Patrick O'day also recently made the following trade(s):
- On Tuesday, April 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00.
Gilead Sciences Stock Performance
Shares of NASDAQ:GILD opened at $127.57 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The stock has a market capitalization of $158.39 billion, a P/E ratio of 17.38 and a beta of 0.31. The firm has a fifty day simple moving average of $135.10 and a two-hundred day simple moving average of $134.26. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analysts' expectations of $6.91 billion. During the same period last year, the company posted $1.81 EPS. The business's revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. On average, analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 44.69%.
Analyst Upgrades and Downgrades
GILD has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Truist Financial reissued a "buy" rating and issued a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Wolfe Research lifted their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a research note on Thursday, February 12th. Morgan Stanley dropped their price target on shares of Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Finally, Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $156.93.
Check Out Our Latest Analysis on GILD
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis, showing statistically significant ALP normalization versus placebo after 52 weeks. This adds to investor optimism around its liver disease franchise and broader growth prospects. Article Title
- Positive Sentiment: Separate coverage highlighted additional favorable Livdelzi data, including long-term efficacy and safety findings and a post hoc analysis showing sustained normalization of a key liver marker in PBC patients. These results reinforce confidence in the drug’s commercial potential. Article Title Article Title
- Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, which can bolster sentiment by signaling improved analyst confidence in the stock’s outlook.
- Positive Sentiment: Cencora announced it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, Yescarta and Tecartus, helping ensure continued commercialization and access for an important Gilead unit. Article Title
- Neutral Sentiment: Gilead also has several upcoming and recent oncology presentations with Kite at ASCO and EHA, which keep the company in focus but do not yet provide a clear near-term financial read-through. Article Title
- Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title
Hedge Funds Weigh In On Gilead Sciences
A number of large investors have recently made changes to their positions in the company. Paulson Wealth Management Inc. boosted its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company's stock worth $477,000 after purchasing an additional 67 shares during the period. Essex Financial Services Inc. boosted its position in Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company's stock valued at $948,000 after buying an additional 71 shares during the period. Davidson Trust Co. boosted its position in Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company's stock valued at $262,000 after buying an additional 74 shares during the period. Alpha Cubed Investments LLC boosted its position in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company's stock valued at $812,000 after buying an additional 75 shares during the period. Finally, Personal CFO Solutions LLC boosted its position in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company's stock valued at $561,000 after buying an additional 76 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
